MHRA Grants UK Patients Early Access to Akcea Therapeutics’ Volanesorsen for Familial Chylomicronaemia Syndrome (FCS)
Akcea Therapeutics United Kingdom (UK) Ltd today announced that volanesorsen has been granted a positive scientific opinion through the Early Access to Medicines Sche...
Continue Reading →
